Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021-Reference-Cited by-同舟云学术

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021

Published:2021-09-02 Issue:35 Volume:26 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Seppälä Elina¹²,Veneti Lamprini³^ORCID,Starrfelt Jostein³^ORCID,Danielsen Anders Skyrud³^ORCID,Bragstad Karoline⁴,Hungnes Olav⁴,Taxt Arne Michael²,Watle Sara Viksmoen²,Meijerink Hinta²

Affiliation:

1. ECDC Fellowship Programme, Field Epidemiology path (EPIET), European Centre for Disease Prevention and Control, (ECDC), Stockholm, Sweden

2. Department of infectious disease control and vaccines, Norwegian Institute of Public Health, Oslo, Norway

3. Department of infectious disease control and preparedness, Norwegian Institute of Public Health, Oslo, Norway

4. Department of virology, Norwegian Institute of Public Health, Oslo, Norway

Abstract

Some variants of SARS-CoV-2 are associated with increased transmissibility, increased disease severity or decreased vaccine effectiveness (VE). In this population-based cohort study (n = 4,204,859), the Delta variant was identified in 5,430 (0.13%) individuals, of whom 84 were admitted to hospital. VE against laboratory confirmed infection with the Delta variant was 22.4% among partly vaccinated (95% confidence interval (CI): 17.0−27.4) and 64.6% (95% CI: 60.6−68.2) among fully vaccinated individuals, compared with 54.5% (95% CI: 50.4−58.3) and 84.4% (95%CI: 81.8−86.5) against the Alpha variant.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference14 articles.

1. European Centre for Disease Prevention and Control (ECDC). SARS-CoV-2 variants of concern as of 15 July 2021. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/en/covid-19/variants-concern

2. European Centre for Disease Prevention and Control (ECDC). Threat assessment brief: implications for the EU/EEA on the spread of the SARS-CoV-2 Delta (B.1.617.2) variant of concern. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/en/publications-data/threat-assessment-emergence-and-impact-sars-cov-2-delta-variant

3. World Health Organization (WHO). Weekly epidemiological update on COVID-19 - 20 July 2021. Geneva: WHO; 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---20-july-2021

4. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant.;Lopez Bernal;N Engl J Med,2021

5. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.;Sheikh;Lancet,2021

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SARS-CoV-2: pathogenesis, therapeutics, variants, and vaccines;Frontiers in Microbiology;2024-06-13

2. Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023;Vaccine;2024-01

3. Boosted production of antibodies that neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following messenger RNA vaccination - a case study;International Journal of Infectious Diseases;2023-12

4. Comparative Pharmacological Efficacy of COVID-19 Vaccines against the Variants of Concerns (VOCs) of SARS-CoV-2: Recent Clinical Studies on Booster Dose;Current Pharmaceutical Biotechnology;2023-11

5. Clinical Severity of SARS-CoV-2 Variants during COVID-19 Vaccination: A Systematic Review and Meta-Analysis;Viruses;2023-09-26